1,717
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Triglyceride-Glucose Index is a Risk Marker of Incident COPD Events in Women

ORCID Icon, , ORCID Icon &
Pages 1393-1401 | Published online: 17 Jun 2022
 

Abstract

Purpose

The triglyceride-glucose index (TyG index) is a marker of insulin resistance and metabolic dysfunction and has the advantage of being universally available. Although recent evidence suggests the TyG index has relevance to respiratory health, there have been no prospective studies assessing its value as a biomarker for chronic lung diseases. We aim to assess the TyG index as a potential risk marker for future incident COPD events in the general population.

Patients and Methods

Baseline TyG index was assessed in 28,282 middle-aged men and women without previous history of chronic obstructive pulmonary disease (COPD) from the Malmö Preventive Project (men between 1974 and 1982 and women between 1982 and 1992). All subjects were followed up prospectively, and Cox proportional hazards regression was used to assess incident COPD events according to quartiles of TyG index.

Results

After an average of 31 years of follow-up, TyG index was a strong predictor of future COPD events even after adjusting for potential confounders (Q4 (highest TyG index) HR (95% CI): 1.21 (1.09–1.35) vs Q1 (reference), p-trend <0.001). After stratifying by sex, the results remained statistically significant in women only (Q4 vs Q1 HR 1.72 (1.41–2.09)). Additionally, the risk remained significant in a cohort of life-long never smokers (Q4 vs Q1 HR 1.47 (1.08–2.01)).

Conclusion

A raised TyG index is a novel risk marker of future incident COPD events in women. Insulin resistance as reflected by the TyG index can precede the development of obstructive lung disease and as such may be an easily measurable and useful predictor of COPD in women.

Disclosure

SZ, HT, PMN and IFM have no conflicts of interests in relation to this work to declare. The baseline screening of participants in the Malmö Preventive Project (MPP) study was supported by the City of Malmö, the Swedish Medical Research Council, and the Swedish Heart and Lung Foundation. All data accessed complied with the relevant data protection and privacy regulations.